Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A group of “immunological nonresponders” wants the FDA to grant them orphan disease status.
Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.
So long as the viral load doesn’t hit 50 or above, there is likely no reason to switch antiretrovirals.
A look at some science-based facts about HIV that may surprise you as we mark the 35th anniversary of the start of the AIDS epidemic.
Starting HIV treatment with a higher viral load tends to increase the time it takes to suppress the virus, extending the window of time when a...
Those who experience virologic failure when taking a first-line ritonavir-boosted protease inhibitor to treat HIV may be better off staying on...
HIV-positive people on treatment who have a persistently detectable viral load, even a very low one, are at an increased risk for treatment fa...
Switching an antiretroviral (ARV) regimen within three months of starting treatment could significantly increase the odds of treatment success...
Study authors stress that the goal of strict adherence for as long as someone remains on HV therapy remains unchanged.
A person’s first antiretroviral (ARV) drug regimen remains the best opportunity he or she has in terms of keeping viral load undetectable, sug...
Drug-level tests may be key in preventing treatment failure.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.